- Home
- Featured Publications
- Center Publications
- Effectiveness of a carbohydrate restricted diet to treat non-alcoholic fatty liver disease in adolescents with obesity: Trial design and methodology.
Effectiveness of a carbohydrate restricted diet to treat non-alcoholic fatty liver disease in adolescents with obesity: Trial design and methodology.
Citation | “Effectiveness Of A Carbohydrate Restricted Diet To Treat Non-Alcoholic Fatty Liver Disease In Adolescents With Obesity: Trial Design And Methodology.”. Contemporary Clinical Trials, pp. 95-101. . |
Center | University of Alabama at Birmingham |
Author | Shima Dowla, May Pendergrass, Mark Bolding, Barbara Gower, Kevin Fontaine, Ambika Ashraf, Taraneh Soleymani, Shannon Morrison, Amy Goss |
Keywords | adolescent, Carbohydrate restriction, Childhood obesity, Diet intervention, non-alcoholic fatty liver disease |
Abstract |
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder among children in the developed world and can progress to cirrhosis, hepatocellular carcinoma, and liver failure. No evidence-based dietary guidelines exist on the most effective diet prescription to treat NAFLD. OBJECTIVE: To compare the effect of a carbohydrate (CHO)-restricted diet vs fat-restricted diet, the current standard of care, on changes in hepatic fat infiltration, body composition, and metabolic health over an 8-week period among overweight and obese children diagnosed with NAFLD. METHODS: In this two-arm, parallel design randomized controlled trial (RCT), 40 participants aged 9 to 18 years were randomized to a CHO restricted diet (<25:>50:25% daily calories from CHO: fat: protein) or control, fat restricted diet (55,20:25% daily calories from CHO: fat: protein). This family-based diet intervention included: (1) a 2-week supply of groceries to feed a four-person household specific to the assigned diet; and (2) extensive education on diet implementation through biweekly, diet-specific group and individualized counseling sessions with participants and one parent or guardian led by a registered dietitian (RD). The primary outcome measure of this study was hepatic lipid, measured using magnetic resonance spectroscopy (MRS). Secondary outcomes included liver transaminases; markers of inflammation (hsCRP, IL-6, TNF-α); body composition; visceral adipose tissue; and insulin resistance. All testing was conducted at baseline and week 8; hepatic transaminases were also measured at weeks 2 and 4. This RCT is registered with ClinicalTrials.gov (ID: NCT02787668). |
Year of Publication |
2018
|
Journal |
Contemporary clinical trials
|
Volume |
68
|
Number of Pages |
95-101
|
Date Published |
12/2018
|
ISSN Number |
1559-2030
|
DOI |
10.1016/j.cct.2018.03.014
|
Alternate Journal |
Contemp Clin Trials
|
PMID |
29601997
|
PMCID |
PMC6411075
|
Download citation |